Thursday, June 16th, 2016 - RnR Market Research

The analysts forecast global cancer immunotherapies market to grow at a CAGR of 15.17% during the period 2016-2020. This report covers the present scenario and the growth prospects of the global cancer immunotherapies market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cancer immunotherapies used to treat cancer.

The following companies are the key players in the global cancer immunotherapies market: Amgen Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, GlaxoSmithKline Plc, Merck Inc., and Takeda Pharmaceuticals. Other Prominent Vendors in the market are: AbbVie, ADC Therapeutics, Agensys, Astellas, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer-Ingelheim, Celgene, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed, Pfizer, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, and XBiotech.

Order a copy of report @

According to the Cancer Immunotherapies market an increased in the demand for cancer monoclonal antibodies will have a big impact on the market. The development and rising demand for cancer monoclonal antibodies have been attributed to the recent understanding of the type of cancer at the molecular level. Monoclonal antibodies have a high affinity for specific disease cells and areas that need treatment. The use of cancer monoclonal antibodies is growing, including therapies such as radio immunotherapy and antibody-directed enzyme prodrug therapy (ADEPT). The rising use of these antibodies in drug development increases the revenue generation in the global cancer monoclonal antibodies market, thereby contributing to market growth.

The global Cancer Immunotherapies market an emergence of targeted and combination therapies are being developed to treat all types of cancer. Targeted therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse effects than conventional non-targeted therapies. For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2. In such circumstances, drugs such as Herceptin and Kadcyla, which target HER2 receptors, are administered as monotherapies or in combination. Targeting multiple pathways reduces the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating cancer.

Inquire more about Global Cancer Immunotherapies Market 2016-2020 report at @

Global Cancer Immunotherapies Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Cancer immunotherapy works by enhancing the innate powers of the immune system. This has better chances of successfully fighting cancer for a long period. Also, immunotherapies have fewer side effects and can treat different types of cancer. Cancer immunotherapies make up nearly 50% of the cancer drugs market.

Further, the report states that the expiry of drug patents will lead to reduced sales of key drugs.

File Library

Contact Profile

RnR Market Research

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus:



RSS / Feeds:

Ritesh Tiwari
P: + 1 888 391 5441


Amgen, Bristol-Myers Squibb, F. Hoffman-La Roche, GlaxoSmithKline, Merck, Takeda Pharmaceuticals, Global Cancer Immunotherapies Market Driver 2016, Cancer Immunotherapies industry, Market Research Reports, Cancer Immunotherapies Market analysis, Cancer




More Formats